Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06579469 · ClinicalTrials.gov registry record
Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy
A clinical trial of Solid Tumor and Hematologic Malignancy, sponsored by St. Jude Children's Research Hospital.
- Recruiting
- Registry status
- 100
- Enrollment target
- 2
- Study locations
NCT06579469 is a study of Solid Tumor and Hematologic Malignancy that is actively recruiting participants, run by St. Jude Children's Research Hospital. The registered enrollment target is 100 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (55% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06579469, a study of Solid Tumor and Hematologic Malignancy, is actively recruiting participants, sponsored by St. Jude Children's Research Hospital.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is being done to learn more about the short-term and long-term side effects of CAR-T cell therapy. Specifically, researchers want to know how often patients get infections, have delays in recovering blood cell counts and/or have damage to the nervous system.
Conditions Studied
Study Locations (2)
Tennessee
- St. Jude Children's Research Hospital - Memphis
Wisconsin
- Children's Hospital of Wisconsin. - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-01-20 |
| Est. Completion | 2029-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06579469
The ClinicalTrials.gov registry entry for NCT06579469 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (55% lower). The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Solid Tumor appearing as the primary indexed condition, and to 0 interventions.
NCT06579469 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Tennessee, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06579469 about?
NCT06579469 is a clinical study titled "Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy". This study is being done to learn more about the short-term and long-term side effects of CAR-T cell therapy. Specifically, researchers want to know how often patients get infections, have delays in recovering blood cell counts and/or have damage to the nervous system.
What is the current status of trial NCT06579469?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2026-01-20. Estimated completion is 2029-03.
What conditions does trial NCT06579469 study?
This clinical trial studies the following conditions: Solid Tumor, Hematologic Malignancy, B-ALL.
Who is sponsoring clinical trial NCT06579469?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06579469 being conducted?
This trial has 2 study locations across Tennessee, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
RECRUITING · Phase 3
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.